Toshiba’s Contrast-free MRA Improve Patient Safety | Toshiba Medical Systems Corporation
LinkedIn Login

Connect healthcare products, companies and hospitals with your LinkedIn network.

Facebook Login

Interact with your Facebook network around healthcare products, companies and hospitals.

Login With Facebook
MedicExchange Login

Enjoy Premium Access as a MedicExchange Member.

       Enter Your Email Address to Receive a
Copy of MedicExhange Member Demograhpics

Facebook Twitter Linkedin
Facebook: MedicExchange
Twitter: MedicExchange
Healthcare Company News Toshiba Medical Systems Corporation Toshiba’s Contrast-free MRA Improve Patient Safety

Toshiba’s Contrast-free MRA Improve Patient Safety

Company News - Toshiba Medical Systems Corporation

In response to concern over Toshiba's gadolinium-based contrast agents, Little Company of Mary, wanted to provide the highest quality and safest MRA procedures to its patients. To accomplish this, the facility installed Toshiba America Medical Systems, Inc.’s Vantage Atlas MR system and utilized the full suite of proprietary contrast-free MRA techniques. These contrast-free techniques proved so beneficial that Little Company of Mary now completes 98 percent of its MRA exams without contrast.

“Eliminating the use of gadolinium-based contrast agents, particularly for patients with renal impairment, is greatly improving patient safety for those undergoing MRA exams at Little Company of Mary,” said Kate Erickson, supervisor of CT and MRI, Little Company of Mary. “The image quality produced using the contrast-free techniques is equal to or better than typical contrast-enhanced MRA exams.”

Erickson also added that Toshiba’s techniques are improving hospital efficiency. For example, by not using contrast the team has reduced the need for rescans that sometimes occurs when a bolus is missed, and they also do not need to run pre-exam lab tests on patients to evaluate renal function.

Little Company of Mary’s utilization of Toshiba’s contrast-free MRA techniques demonstrates their real-world effectiveness in delivering high image quality while eliminating the risks of gadolinium-based contrast agents,” said Doug Ryan, vice president, Marketing and Strategic Development, Toshiba. “As the risks of gadolinium-based contrast agents are not fully known, it is important that the imaging community continue to offer these advanced techniques.”

Gadolinium-based contrast agents, the most common contrast agents used for MRA, have been directly linked to nephrogenic systemic fibrosis or nephrogenic fibrosing dermopathy (NSF/NFD) a sometimes fatal skin disease that occurs in patients with renal insufficiency. To combat this issue, Toshiba developed the industry’s only full suite of advanced contrast-free MRA techniques that are available on the entire Vantage MR product line. These techniques include Fresh Blood Imaging (FBI), Contrast-free Improved Angiography (CIA), Time-Spatial Labeling Inversion Pulse (Time-SLIP) and Time and Space Angiography (TSA).

Source: Toshiba

You can discuss about Toshiba and its products & services in the Toshiba User Group